2021
DOI: 10.1101/2021.02.18.431922
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

ESC - a comprehensive resource for SARS-CoV-2 immune escape variants

Abstract: Ever since the breakout of COVID-19 disease, ceaseless genomic research to inspect the epidemiology and evolution of the pathogen has been undertaken globally. Large scale viral genome sequencing and analysis have uncovered the functional impact of numerous genetic variants in disease pathogenesis and transmission. Emerging evidence of mutations in spike protein domains escaping antibody neutralization is reported. We have a precise collation of manually curated variants in SARS-CoV-2 from literature with pote… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 44 publications
2
1
0
Order By: Relevance
“…Similar clinical findings were also documented by Philomina et al in breakthrough infections in six people receiving two doses of ChAdOx1 nCoV-19/Covishield vaccine in Kerela [21]. In a recent study of breakthrough infections from Delhi, including a mixed cohort of HCWs, 10 received ChAdOx1 nCoV-19/Covishield vaccine and 53 received BBV152/Covaxin and none had severe infection [22]. Thus, two doses of ChAdOx1 nCoV-19/Covishield vaccine offer protection against moderate to severe COVID-19 disease.…”
Section: Discussionsupporting
confidence: 81%
“…Similar clinical findings were also documented by Philomina et al in breakthrough infections in six people receiving two doses of ChAdOx1 nCoV-19/Covishield vaccine in Kerela [21]. In a recent study of breakthrough infections from Delhi, including a mixed cohort of HCWs, 10 received ChAdOx1 nCoV-19/Covishield vaccine and 53 received BBV152/Covaxin and none had severe infection [22]. Thus, two doses of ChAdOx1 nCoV-19/Covishield vaccine offer protection against moderate to severe COVID-19 disease.…”
Section: Discussionsupporting
confidence: 81%
“…It is known that B.1.617.2 is characterised by 3 spike mutations L452R, T478K and P681R. 7 B.1.617.1 is characterized L452R, E484Q and P681R 23. Similar predominance of B.1.617.2 in vaccinated individuals, was also reported from another tertiary care centre in Delhi during the surge of infections during March and April 6.…”
supporting
confidence: 57%
“…ESC_Comprehensive resource of immune escape variants in SARS-COV-2 was used to detect the escape mutants in S-protein ( http://clingen.igib.res.in/esc/ ). [ 7 ]…”
Section: Ethodsmentioning
confidence: 99%